Articles tagged with Alzheimer Disease
Researchers have identified networks of changing proteins specific to Alzheimer's disease, highlighting the importance of inflammation and microglia. By analyzing post-mortem brain proteins, they uncovered patterns pointing to glial cell involvement in the disease's pathogenesis.
Rates of dementia and Alzheimer's disease are higher among older kidney transplant recipients than in the general population. Older patients with kidney failure who receive a kidney transplant are at increased risk of developing these conditions, which can threaten both their transplanted organ and survival.
Scientists found abnormal immune reactions in the brain's cerebrospinal fluid seven years before expected dementia onset. TREM2 levels can track immune activity and predict disease progression.
A USC study found that men and women taking statins for two years or more had a reduced risk of Alzheimer's disease. High users of statins, particularly Hispanic men, saw significant drops in incidence rates.
A study analyzing Medicare data found a link between statin use and reduced Alzheimer's disease risk. The association varied by statin type and race/ethnicity, highlighting the need for further clinical trials to confirm these findings.
Researchers developed a vaccine that stimulates an antibody targeting pathological tau, discovering its Achilles' heel. The antibody avoids immune reaction towards the body by coupling to a carrier molecule.
A recent study from the University of Eastern Finland found that hip fracture risk is higher among those with Alzheimer's disease. Regular assessments of medications and targeted interventions such as exercise, home safety assessment and modification, and medication reviews are proposed as feasible approaches to reduce this risk.
Researchers found that harmine increases proliferation of human neural progenitor cells by inhibiting DYRK1A, leading to a 70% increase in new neural cell generation. This effect may lead to potential therapeutic applications for depression and neurodegenerative diseases.
A study published in ACS Central Science reveals that MAO activity increases with Aβ plaque formation in patients with Alzheimer's, suggesting it could serve as a biomarker for diagnosis and monitoring. The research also identified three distinct phases of MAO activity that change along with disease progression.
Researchers at MIT have developed a noninvasive technique using LED lights to reduce beta amyloid plaques in mouse models of Alzheimer's disease. The treatment induces gamma oscillations, which suppress beta amyloid production and invigorate cells responsible for destroying the plaques.
Researchers at the Salk Institute identified a microprotein involved in clearing out genetic material that's no longer needed, shedding light on gene regulation and mRNA recycling. The discovery highlights the importance of overlooked microproteins and their potential role in disease.
Researchers at Einstein College of Medicine and Penn State University will use smartphones to assess cognitive changes in seniors with Alzheimer's disease. The five-year study aims to develop personalized interventions to prevent dementia by analyzing risk factors such as stress, pain, and sleep.
Researchers at OHSU discovered a correlation between aquaporin-4 prevalence in brains of older people without Alzheimer's compared to those with the disease. The protein's disorganization in Alzheimer's brains may reflect impaired waste clearance, suggesting it as a potential target for treatment or prevention.
A recent study found that approximately one-third of Alzheimer's patients use prescription pain relievers, comparable to those without the disease. However, the type and frequency of analgesics used differed significantly between groups. Paracetamol was most commonly used, while anti-inflammatory medications were less frequent.
The study found that benzodiazepine and related drug use increased the risk of hip fracture by 43% in persons with Alzheimer's disease. Long-term hospital stays after hip fractures were also more common among those who used these drugs.
A recent study found memantine and rivastigmine patches increase pneumonia risk by 1.6 and 1.15 times, respectively. In contrast, donepezil and galantamine were associated with the lowest risk of pneumonia.
A randomized trial involving 180 Alzheimer's patients found that occupational therapy did not slow the loss of physical function, despite tailored to individual patient needs. The results underscore the burden on caregivers and highlight the need for additional support strategies, such as home modifications and assistive devices.
Researchers identified a protein called kinase p38γ that assists protective phosphorylation of tau and interferes with amyloid-beta toxicity. Introducing the protein into mice brains prevented memory deficits associated with Alzheimer's disease.
Researchers developed an improved animal model of Alzheimer's disease using tau protein isolated from patient brains. The model replicates the formation and spread of brain fibrils associated with AD, offering new opportunities for investigating therapies to stop or slow their progression.
Senior officials from the FDA and NIA joined advocates and researchers to discuss collaborations for advancing Alzheimer's disease knowledge into clinical trials. The meeting aimed to identify reliable biomarkers and symptomatic approaches to improve treatment of major behavioral and psychiatric aspects of the disease.
Researchers at Tel Aviv University have identified a gene that may permit early detection of Alzheimer's disease. The RGS2 gene is involved in neurotransmission signaling and its reduced expression increases the sensitivity of brain neurons to toxic effects of amyloid-β, a protein associated with the disease.
Researchers found that Ceftriaxone reduces synaptic disruption and clears neuronal lines of communication in mice with Alzheimer's disease. Amyloid plaques prevent cell communication, leading to nerve cell death. The antibiotic restores glutamate levels, mostly restoring neuronal activity.
A recent study found that one-third of people initiating opioid use became long-term users, particularly those using transdermal patches. Long-term opioid use was comparable to that of non-dementia individuals, but combined with benzodiazepines, it poses a significant risk.
A non-invasive test measuring odor recognition and recall can identify older individuals at increased risk of Alzheimer's disease. The study found that participants with poor performance in the test were more likely to have a variant of the APOE gene associated with increased Alzheimer's risk.
A daily dose of probiotic Lactobacillus and Bifidobacterium bacteria taken over 12 weeks significantly improved the Mini-Mental State Examination (MMSE) score in Alzheimer's patients, indicating a moderate but significant improvement in cognitive function. This is the first study to show that probiotics can benefit human cognition.
Researchers found specific changes in memory function that correspond to sex and menopausal stage, implicating key areas of the brain vulnerable to age-related decline. Hormone measurements revealed higher estradiol levels correlate with better memory performance in women.
New research reveals that toxic proteins in neurodegenerative diseases like Alzheimer's spread through the brain via synapses, with genetic risk factors playing a critical role. Understanding this mechanism opens new perspectives for treatment and potential therapeutic avenues to block protein transmission.
Researchers found people with early Alzheimer's disease have different daily patterns of activity than those without the disease, spending less time in moderate-intensity activities. Customized interventions targeting morning physical activity may help improve sleep and slow cognitive decline.
Researchers at Tohoku University have discovered a potential link between Alzheimer's disease and insulin signaling dysfunction. The study suggests that memantine, an Alzheimer's treatment, can improve cognitive function by inhibiting the ATP-sensitive potassium channel (Kir6.2 channel), leading to better memory retention in patients.
A recent study published in Brain and Cognition found that lexical and semantic knowledge related to food is relatively well preserved even in diseases like Alzheimer's and Aphasia Primary Progressive. Food information was processed better than non-food, with caloric foods being more resiliently remembered.
Researchers challenge the widely held belief that Alzheimer's disease originates in the temporal lobe by identifying the basal forebrain region as a critical area of degeneration. The study shows that degeneration in this region predicts subsequent spread to other brain areas, opening new avenues for detection and intervention.
Scientists developed two types of llama antibody that can specifically mark and show amyloid plaques and neurofibrillary tangles, the characteristic lesions of Alzheimer's disease. These antibodies have the rare ability to cross the blood-brain barrier, allowing for non-invasive detection.
Researchers suggest shifting from 'curing' Alzheimer's to building resilience, acknowledging the disease is intertwined with aging processes. They propose education, infrastructure support and proper care as key components of societal response.
Higher cortical amyloid levels associated with greater loneliness, particularly in APOE4 carriers. Participants with higher amyloid levels were 7.5 times more likely to be classified as lonely than non-lonely individuals.
A study has discovered a crucial part of the genetic machinery that switches on the Neuroglobin gene, which is associated with protecting the brain and reducing severity of damage due to stroke and Alzheimer's disease. The research opens up new opportunities for treating AD using gene therapy.
Researchers developed a new chemical compound Fluselenamyl that detects amyloid clumps better than current FDA-approved compounds. It potentially could be used in brain scans to identify early-stage Alzheimer's disease or monitor response to treatment.
Claudia Satizabal, a Boston University researcher, has received an Alzheimer's Association research grant to investigate the impact of midlife obesity on brain aging and dementia. Her study aims to understand the mechanisms by which obesity increases the risk of dementia and AD.
A new study published in Neurology found that people with thinking and memory problems who lack shrinkage in the hippocampus area of the brain are more likely to develop dementia with Lewy bodies. This finding could help doctors identify patients at risk for the disease and provide early treatment.
Researchers developed a potent and well-tolerated BACE1 inhibitor, verubecestat, which safely reduced toxic β-amyloid levels in AD patients. The drug has shown promise in clearing amyloid plaques and is currently advancing to phase 3 trials.
A new study published in Neurology suggests that a lack of hippocampus shrinkage may indicate an increased risk of developing dementia with Lewy bodies. The study found that individuals with normal hippocampus volume were 5.8 times more likely to develop probable dementia with Lewy bodies than those with atrophy.
Researchers found that distinct tau aggregate conformations cause different pathological patterns in the brain, affecting specific regions and progressing at varying rates. This discovery has implications for developing targeted therapies and diagnosing dementias.
Researchers found that chronic low-dose-rate ionizing radiation can induce molecular changes in the brain resembling Alzheimer's disease. Studies exposed mice to cumulative doses of radiation, inducing changes in the hippocampus, a key region for learning and memory.
A novel approach to analyzing brain structure shape reveals structural asymmetries that vary among individuals, increasing with disease severity. This technique, BrainPrint, may predict disease progression and allow early detection of dementia.
NTRX-07 targets cause of Alzheimer's disease, reducing inflammation and preserving neurons. The new drug improves removal of abnormal amyloid plaques, memory performance, and cognitive skills in mice.
The Phase 3 analyses of tramiprosate in patients with Mild to Moderate Alzheimer's disease show a gene-dose effect, with the largest clinical benefit seen in patients who are APOE4/4 homozygotes. These results suggest that tramiprosate could be an effective treatment for patients with this genetic risk factor.
Researchers created a novel nematode strain that produces amyloid beta protein fragments, displaying neuromuscular defects and age-dependent behavioral dysfunction. The findings suggest mitochondrial bioenergetic deficit as an early event in Alzheimer's disease.
Research from Newcastle University found that aging brains lose their youthful folding pattern due to decreasing cortical tension. The study provides a new method for measuring brain folding and could help diagnose Alzheimer's disease.
Researchers at the University of Arizona Health Sciences aim to unlock the mystery of Alzheimer's disease in women, who are disproportionately affected by the neurodegenerative brain disease. The five-year National Institute on Aging program project grant will investigate biological transformations during perimenopause that may increas...
Scientists at Baylor College of Medicine identified a potential new strategy to prevent Alzheimer's disease by inhibiting the enzyme Nuak1, which reduces tau accumulation in the brain. The study used a three-pronged approach and confirmed results in human cells, fruit flies, and mouse models.
A new study published in Cell Reports identifies two proteins relevant to Alzheimer's disease, Interleukin-4 and STAT6, which play a crucial role in neural stem cell proliferation and formation of new neurons. This discovery offers hope for the development of regenerative therapies for Alzheimer's.
Researchers analyzed blood plasma levels of tau protein in patients with early onset psychosis (EOP) aged 18 and under, finding higher levels than controls. The study suggests altered tau protein metabolism in EOP, which may have implications for understanding the pathophysiology and developing new treatment strategies.
Researchers discovered a rare genetic variant in TM2D3 linked to late-onset Alzheimer's disease among Icelandic participants. The variant is estimated to increase the risk of Alzheimer's by approximately six times.
Researchers identified a novel rare mutation in the TM2D3 gene associated with an increased risk of late-onset Alzheimer's disease. The variant is approximately 10 times more common in Icelanders than in the European population, yet remains rare and present in fewer than 1% of the Icelandic population.
The National Alzheimer Project Act lacks a strategy to determine the clinical benefit of investigational drugs, potentially leading to exploitation by private interests. Authors propose three key questions to address this issue: slowing cognitive decline, lengthening disease stages, and delaying death.
Boston University School of Medicine professor Sudha Seshadri has been awarded three grants totaling $20 million to study healthy brain aging, stroke, and dementia. Her research aims to identify biomarkers for AD and explore reversible lifestyle and vascular risk factors that contribute to dementia risk.
A novel optical sensor has been developed to detect vitamin B12 in human blood serum, enabling early intervention and tracking of levels in high-risk patients. The device uses Raman spectroscopy to produce a unique optical fingerprint of vitamin B12, offering a promising first step towards a point-of-care solution.
A team of scientists identified how amyloid beta, associated with Alzheimer's, can induce cellular changes leading to Parkinson's. This discovery may provide an explanation for the co-occurrence of these neurodegenerative conditions and help researchers find ways to prevent such cases.
A new study suggests that air pollution, vitamin D deficiency, and occupational exposure to certain pesticides may contribute to dementia risk. The research highlights the importance of addressing environmental factors in preventing or delaying the onset of the disease.
Researchers have prevented the development of Alzheimer's disease in mice by using a virus to deliver a specific gene, PGC-1 - alpha, into the brain. The study opens avenues for potential new treatments for the disease and suggests that injections of the gene may be beneficial in the early stages of the disease.
Researchers identified three distinct brain atrophy patterns associated with cognitive decline in Alzheimer's disease and mild cognitive impairment. The study found that these patterns, including cortical, temporal, and subcortical atrophy, can predict cognitive deficits and may allow for earlier diagnosis and treatment.